Company news

Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news

Biocryst Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 5, 2026: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease…

Biocryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news

Press releases & updates

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Report First Quarter 2026 Financial Results on May 6

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals : Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Astria Stockholders Vote to Approve Acquisition by BioCryst

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

BioCryst to Present at Upcoming Investor Conference

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst to Report Third Quarter 2025 Financial Results on November 3

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst to Present at Upcoming Investor Conferences

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years